HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

(2010) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab

(2009) A. Magnifico et al.   CLINICAL CANCER RESEARCH

Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout

(2009) M. Versele et al.   MOLECULAR CANCER THERAPEUTICS

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion

(2008) H Korkaya et al.   ONCOGENE

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells

(2008) Anthony Kong et al.   PLoS One